Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Survival Motor Neuron Protein (Component of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development Report Overview
Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The Survival motor neuron protein (Component of Gems 1 or Gemin 1 or SMN1 or SMN2) drugs in development research report provides comprehensive information on the therapeutics under development for survival motor neuron protein. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication.
The pipeline report covers the descriptive pharmacological action and product description of SMN1. It includes the complete research and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in survival motor neuron protein (SMN1) therapeutic development and features dormant and discontinued products.
Buy the Full Report to Know More about the Survival Motor Neuron Protein Pipeline Products
Key Therapy Area | · Central Nervous System |
Key Indications | · Spinal Muscular Atrophy (SMA)
· Huntington Disease |
Key Mechanism of Action | · Survival Motor Neuron Protein Activator |
Key Molecule Types | · Gene Therapy
· Small Molecule · Antisense Oligonucleotide |
Key Routes of Administration | · Oral
· Intravenous · Intrathecal |
Leading Companies | · Amogen Pharma Pvt Ltd
· Beijing GeneCradle Technology Co Ltd · Biocad · CANbridge Life Sciences Ltd · F. Hoffmann-La Roche Ltd |
Enquiry & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
SMN1 Pipeline Products Segmentation by Therapy Area and Indications
The only key therapy area associated with SMN1 drugs in development is the central nervous system. The key indications for SMN1 drug application include Spinal Muscular Atrophy (SMA) and Huntington Disease. Survival motor neuron protein drugs had the highest number of products in development for Spinal Muscular Atrophy (SMA) in 2022.
Survival Motor Neuron Protein Pipeline Products Analysis by Indications, 2022 (%)
Buy the Full Report for More Therapy Area and Indication Insights into the SMN1 Pipeline Products
SMN1 Pipeline Products Segmentation by MoA and Molecule Types
The only mechanism of action in SMN1 drugs in development is the Survival Motor Neuron Protein Activator. The key molecule types associated with SMN1 drugs in development are gene therapy, small molecule, and antisense oligonucleotide. Gene therapy accounted for the highest molecule type share of survival motor neuron protein drugs in development in 2022.
Survival Motor Neuron Protein Pipeline Products Analysis by Molecule Types, 2022 (%)
Buy the Full Report for More Molecule Type Insights into the SMN1 Pipeline Products
SMN1 Pipeline Products Segmentation by Routes of Administration
Oral, intravenous, and intrathecal methods can administer the survival motor neuron protein drugs. Oral RoA was the most preferred way for SMN1 drug administration in 2022.
Survival Motor Neuron Protein Pipeline Products Analysis by Routes of Administration, 2022 (%)
Buy the Full Report for More RoA Insights into the SMN1 Pipeline Products
SMN1 Pipeline Products - Competitive Landscape
A few of the leading companies associated with survival motor neuron protein pipeline products are:
- Amogen Pharma Pvt Ltd
- Beijing GeneCradle Technology Co Ltd
- Biocad
- CANbridge Life Sciences Ltd
- Hoffmann-La Roche Ltd
JSC Biocad: Biocad is headquartered in Saint Petersburg, Russia. It is a biotechnology company that conducts research and development services. The company develops, manufactures, and distributes generic pharmaceutical products. It develops products in the form of suppositories, sprays, and drops. Biocad manufactures products in therapeutic areas such as oncology, rare diseases, autoimmune diseases, and infectious diseases.
Survival Motor Neuron Protein Pipeline Products Analysis by Companies, 2022 (%)
Buy the Full Report for More Company Insights into the SMN1 Pipeline Products
SMN1 Pipeline Products - Featured News
13th October 2022: CANbridge Pharmaceuticals Inc. is a leading global biopharmaceutical company with a foundation in China and is committed to the research, development, and commercialization of transformative rare disease and rare oncology therapies. The company announced that data from its gene therapy research agreement with the Horae Gene Therapy Center, at the UMass Chan Medical School, was presented at the 29th European Society of Gene and Cell Therapy Annual Congress in Edinburgh, Scotland.
Buy the Full Report to Know More Featured News about SMN1 Pipeline Products
Segments Covered in the Report
Survival Motor Neuron Protein Pipeline Products Therapy Area Outlook (2022)
- Central Nervous System
Survival Motor Neuron Protein Pipeline Products Indication Outlook (2022)
- Spinal Muscular Atrophy (SMA)
- Huntington Disease
Survival Motor Neuron Protein Pipeline Products MoA Outlook (2022)
- Survival Motor Neuron Protein Activator
Survival Motor Neuron Protein Pipeline Products RoA Outlook (2022)
- Oral
- Intravenous
- Intrathecal
Survival Motor Neuron Protein Pipeline Products Molecule Type Outlook (2022)
- Gene Therapy
- Small Molecule
- Antisense Oligonucleotide
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of SMN protein.
- The pipeline guide reviews pipeline therapeutics for SMN protein by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products that comprise product description, descriptive licensing and collaboration details, R&D brief, MoA, & other developmental activities.
- The pipeline guide reviews key companies involved in SMN protein therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates SMN protein therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for SMN protein.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for SMN protein.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the SMN protein pipeline depth and focus on Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Beijing GeneCradle Technology Co Ltd
Biocad
CANbridge Life Sciences Ltd
F. Hoffmann-La Roche Ltd
Huida (Shanghai) Biotechnology Co Ltd
Novartis AG
Novartis Gene Therapies
Sarepta Therapeutics Inc
Shift Pharmaceuticals
Spotlight Innovation Inc (Inactive)
Suzhou GenAssist Therapeutics Co Ltd
Voyager Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the leading indication for SMN1 drugs in development in 2022?
Survival motor neuron protein drugs had the highest number of products in development for Spinal Muscular Atrophy (SMA) in 2022.
-
Which was the leading molecule type for SMN1 drugs in development in 2022?
Gene therapy accounted for the highest molecule type share of survival motor neuron protein drugs in development in 2022.
-
Which was the leading route of administration for SMN1 drugs in development in 2022?
Oral RoA was the most preferred way for survival motor neuron protein drug administration in 2022.
-
Which are the leading companies associated with SMN1 drugs in development?
A few of the leading companies associated with the survival motor neuron protein pipeline products are Amogen Pharma Pvt Ltd, Beijing GeneCradle Technology Co Ltd, Biocad, CANbridge Life Sciences Ltd, and F. Hoffmann-La Roche Ltd, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.